On Friday, the Food and Drug Administration approved the first test for cervix skirting screening, which was developed by the startup Teal Health based in San Francisco.
The company started developing the prototype for its blue -green wand a little more than five years ago. The concept consisted of telegesenship and a test that could be administered at home itself, and not more accessible in a doctor's office.
“Pandemic showed everyone that telemedicine is one thing that is preferred … and made it easier to take care of most Americans,” said Kara Egan, CEO of Teal Health and added that Covid also demonstrated “was a thing with which people could handle and really understand.”
The blue -green magic wand works like a tampon applicator, with a large swab that the user can insert to collect an example for testing. The FDA described the tool as a breakthrough after the company's clinical study results showed that the precision of the self-governing test was comparable to an in-offices screening carried out by a clinician with an accuracy rate of 96%.
Teal plans to enable the wand in California first in June.
More CNBC health insurance
With freight forwarders, the company discussed insurance cover for the test as a preventive screening, which would be covered for most women like an annual doctor visits without copays.
The American Cancer Society recommends that women from the age of 21 are examined for cervical cancer every three years.
However, Egan says that 1 of 4 women fall back during screening, also because they cannot find time for a personal gynecologist appointment, especially for women in rural areas who often have to travel beyond their community to get to a doctor.
“This is about increasing access to care and ensuring that we have more options to get this care,” she said.
Before his expected FDA approval, Teal Health collected 10 million US dollars in January in January to improve production for the start of the teal magic. The investment was led by Forerunner Ventures and Laurene Powell Jobs' Emerson Collective. The company has collected a total of 23 million US dollars from Serena Williams' Serena Ventures and test company Labcorp.
The company's milestone comes because investors are more interested in women's health technology.
Last year, according to Deloitte data, there was an influx of $ 680 million in the place invested in 30 shops. According to Jen Radin, headmaster in Deloitte, Deloitte, Deloitte, Deloitte, in Deloitte, around 60% of these funds went in later level and health practice.
“From 2023 to 2024, FemTech recorded growth of 41% and exceeded general health technology, which only grew by 10%,” said Radin.
Femhealth Ventures Managing Partner Maneesha Ghiya says that investors are now more careful to generally go out of interest in women's health technology beyond motherhood and menopause.
“Many other people think more about the health of women and support this type of innovations – and this includes the large, established actors such as Medtech, Pharma, Biotech and large public companies that think more about the health of women,” said Ghiya.
Comments are closed.